Multidisciplinary Association for Psychedelic Studies

United States: The Case for Treating PTSD in Veterans With Medical Marijuana

Studies have already shown the benefits of marijuana for those suffering from PTSD, but can our government agencies be convinced?

By Martin Mulcahey, The Atlantic

There is a truth that must be heard! Researchers are one bureaucratic hurdle away from gaining approval for the first clinical examination on the benefits of marijuana for veterans suffering from post-traumatic stress disorder (PTSD). The Multidisciplinary Association for Psychedelic Studies (MAPS), working under the auspices of the University of Arizona College of Medicine, are preparing a three-month study of combat veterans who served in Iraq and Afghanistan. The plan is on hold until the National Institute on Drug Abuse and Public Health Service (part of the Department of Health and Human Services) agrees to sell researchers the marijuana needed for research -- or until the marijuana can be legally imported. Social and political intrigue surrounding this research is far reaching, attracting opposing factions who must cede biases for the greater good and well-being of servicemen and servicewomen.

Syndicate content